We have 3 of 127 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Immunotherapy, whether administered alone or in combination with chemotherapy, provides significant survival benefits in patients with advanced driver mutation–negative NSCLC, and is evaluated using the GRADE framework.
BIA shows a strong to very strong correlation with DXA but poor concordance for every body composition and bone parameter in paediatric CKD stages 3–5, with clinically unacceptable limits of agreement.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
